Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C33H47NO13 |
Molecular Weight | 665.7252 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 14 / 14 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@H](O)C[C@]3(O)C[C@H](O)[C@@H](C(O)=O)[C@]([H])(C[C@@]([H])(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](N)[C@@H]4O)\C=C\C=C\C=C\C=C\C[C@@H](C)OC(=O)\C=C\[C@@]1([H])O2)O3
InChI
InChIKey=NCXMLFZGDNKEPB-FFPOYIOWSA-N
InChI=1S/C33H47NO13/c1-18-10-8-6-4-3-5-7-9-11-21(45-32-30(39)28(34)29(38)19(2)44-32)15-25-27(31(40)41)22(36)17-33(42,47-25)16-20(35)14-24-23(46-24)12-13-26(37)43-18/h3-9,11-13,18-25,27-30,32,35-36,38-39,42H,10,14-17,34H2,1-2H3,(H,40,41)/b4-3+,7-5+,8-6+,11-9+,13-12+/t18-,19-,20+,21+,22+,23-,24-,25+,27-,28+,29-,30+,32+,33-/m1/s1
Molecular Formula | C33H47NO13 |
Molecular Weight | 665.7252 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 14 / 14 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
https://en.wikipedia.org/wiki/Natamycin
http://www.life-worldwide.org/fungal-diseases/natamycin
http://www.drugbank.ca/drugs/DB00826
Curator's Comment: description was created based on several sources, including:
https://en.wikipedia.org/wiki/Natamycin
http://www.life-worldwide.org/fungal-diseases/natamycin
http://www.drugbank.ca/drugs/DB00826
Natamycin (Pimaricin, Pimafucin, Natadrops, Natacyn) is a polyene antifungal agent originally isolated from Streptomyces natalensis found in a soil sample from Natal, South Africa. Natamycin was discovered in DSM laboratories in 1955. Similar to other polyenes, natamycin binds to ergosterol in the fungal cell membrane. Natamycin blocks fungal growth by binding specifically to ergosterol with¬out permeabilizing the membrane where it inhibits vacuole fusion at the priming phase and interferes with membrane protein functions. Natamycin is also used in the food industry as an effective preservative. Natamycin is active against most Candida spp. Aspergillus spp., Fusarium spp. and other rarer fungi that cause keratitis. Secondary or acquired resistance is probably rare, but not extensively studied. Natamycin is not effective in vitro against gram-positive or gram-negative bacteria. Topical administration appears to produce effective concentrations of natamycin within the corneal stroma but not in intraocular fluid. Natamycin is poorly soluble in water and not absorbed through the skin or mucous membranes, including the vagina. Very little is absorbed through the gastrointestinal tract. After ocular application, therapeutic concentrations are present within the infected cornea, but not in intra-ocular fluid Natamycin may cause some irritation on skin or mucous membranes
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2364028 Sources: http://www.drugbank.ca/drugs/DB00826 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | NATACYN Approved UseNATACYN® (natamycin ophthalmic suspension) 5% is a sterile, antifungal drug for topical ophthalmic administration. Launch Date1980 |
|||
Curative | NATACYN Approved UseNatamycin Launch Date1980 |
|||
Curative | NATACYN Approved UseNatamycin Launch Date1980 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32315560/ |
2.5 μL single, ocular dose: 2.5 μL route of administration: Ocular experiment type: SINGLE co-administered: |
NATAMYCIN plasma | Oryctolagus cuniculus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.72 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32315560/ |
2.5 μL single, ocular dose: 2.5 μL route of administration: Ocular experiment type: SINGLE co-administered: |
NATAMYCIN plasma | Oryctolagus cuniculus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.78 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32315560/ |
2.5 μL single, ocular dose: 2.5 μL route of administration: Ocular experiment type: SINGLE co-administered: |
NATAMYCIN plasma | Oryctolagus cuniculus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:24:32 GMT 2023
by
admin
on
Fri Dec 15 15:24:32 GMT 2023
|
Record UNII |
8O0C852CPO
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
JECFA EVALUATION |
INS-235
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
||
|
NDF-RT |
N0000007672
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
||
|
WHO-VATC |
QG01AA02
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
||
|
WHO-VATC |
QD01AA02
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
||
|
EPA PESTICIDE CODE |
51102
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
||
|
WHO-VATC |
QA01AB10
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
||
|
WHO-ATC |
A01AB10
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
||
|
WHO-ATC |
S01AA10
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
||
|
WHO-VATC |
QA07AA03
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
||
|
NDF-RT |
N0000175936
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
||
|
WHO-VATC |
QS01AA10
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
||
|
WHO-ATC |
A07AA03
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-235
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
||
|
CFR |
21 CFR 172.155
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
||
|
WHO-ATC |
D01AA02
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
||
|
NCI_THESAURUS |
C514
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
||
|
WHO-ATC |
G01AA02
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m7779
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | Merck Index | ||
|
578
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
517
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
8O0C852CPO
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
7268
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | RxNorm | ||
|
natamycin
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
1885
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
SUB09169MIG
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200656
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
DB00826
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
DTXSID6021163
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
8O0C852CPO
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
NATAMYCIN
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
759167
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
D010866
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
7681-93-8
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
100000080343
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
5284447
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
C47634
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
868
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
1457505
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY | |||
|
231-683-5
Created by
admin on Fri Dec 15 15:24:32 GMT 2023 , Edited by admin on Fri Dec 15 15:24:32 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |